Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-8591 in Advanced Acute Myeloid Leukemia (AML)
NCT05947344Phase 1Recruiting
- Sponsor
- ACEA Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ac0939 in acute myeloid leukemia (AML) (2 arms), sponsored by ACEA Pharmaceuticals. Primary endpoint: Number of participants with treatment-related adverse events up to 3 years. Started Dec 2023; status: recruiting.
02
Drugs
ac0939
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05947344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947344.